Case Report: Pathological Complete Response to Neoadjuvant Alectinib in a Patient With Resectable ALK-Positive Non-Small Cell Lung Cancer

• Egile Nagusiak: Yan Hu (Egilea), Siying Ren (Egilea), Ruoyao Wang (Egilea), Wei Han (Egilea), Peng Xiao (Egilea), Li Wang (Egilea), Fenglei Yu (Egilea), Wenliang Liu (Egilea)
• Formatua: Liburua
• Argitaratua: Frontiers Media S.A., 2022-07-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Background: Alectinib, a highly selective inhibitor of ALK, is currently used in the first-line setting of untreated advanced ALK-positive NSCLC and in the second-line setting of crizotinib-resistant ALK-positive NSCLC. Despite promising efficacy and tolerability in the treatment of advanced ALK-pos...